Milestone Pharmaceuticals Inc. - 8-K Filing
Milestone Pharmaceuticals reported $0.2 million in product revenue and a net loss of $26.1 million ($0.20 per share) for Q1 2026. The company has $184.2 million in cash, providing runway through H2 2027. CARDAMYST nasal spray is gaining traction with over 560 patients treated and 400 unique prescribers, while the Phase 3 trial for AFib-RVR will begin in H2 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MIST